Bouros D, Schiza S, Siafakas N
Dept of Pneumonology, Medical School, University of Crete, Greece.
Monaldi Arch Chest Dis. 1999 Jun;54(3):258-63.
Intrapleural instillation of fibrinolytic agents has been shown, in a number of studies, to be an effective and safe mode of treatment in complicated parapneumonic effusions and empyema, minimizing the need for surgical intervention. Streptokinase and urokinase are the fibrinolytics used, but the technique of instillation is not yet standardized. The usual dose of streptokinase is 250,000 IU, 100,000 IU for urokinase. Fibrinolytics are diluted in 30-100 mL normal saline and the success rate ranges 50-100%, depending on the stage of pleural effusion. Generally, fibrinolytics are more successful if used early in the process of pleural infection (in complicated parapneumonic effusions rather than in empyemas). Adverse reactions are rare, of the allergic type and more frequent for streptokinase. Urokinase is safer but more expensive.
多项研究表明,在复杂性肺炎旁胸腔积液和脓胸的治疗中,胸膜腔内注入纤溶药物是一种有效且安全的治疗方式,可减少手术干预的需求。使用的纤溶药物是链激酶和尿激酶,但注入技术尚未标准化。链激酶的常用剂量为250,000国际单位,尿激酶为100,000国际单位。纤溶药物用30 - 100毫升生理盐水稀释,成功率在50% - 100%之间,具体取决于胸腔积液的阶段。一般来说,如果在胸膜感染过程早期(在复杂性肺炎旁胸腔积液而非脓胸时)使用纤溶药物,成功率更高。不良反应很少见,多为过敏类型,链激酶更常见。尿激酶更安全但更昂贵。